AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21480032 — intervention group
Group type: COMPARATOR
Intervention: Wait list comparison group (control)
Number of subjects: 98
Study 18345020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein hydrolysate (PPH)
Number of subjects: 39
Study 18345020 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP)
Number of subjects: 39
Study 18345020 — intervention group
Group type: COMPARATOR
Intervention: Milk protein (MP)
Number of subjects: 39
Study 18345020 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein + pea protein hydrolysate (WP+PPH)
Number of subjects: 39
Study 17139217 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential lumbar fusion
Number of subjects: 148
Study 17139217 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion
Number of subjects: 148
Study 12685616 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin ER/lovastatin 2,000/40 mg
Number of subjects: 237
Study 12685616 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin ER/lovastatin
Number of subjects: 237
Study 12685616 — intervention group
Group type: COMPARATOR
Intervention: lovastatin 40 mg
Number of subjects: 237
Study 10881247 — intervention group
Group type: EXPERIMENTAL
Intervention: OXC 2400 mg/day
Number of subjects: 79
Study 10881247 — intervention group
Group type: COMPARATOR
Intervention: OXC 300 mg/day
Number of subjects: 79
Study 9192926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sidestream nebulizer driven by CR50 air compressor
Number of subjects: 173
Study 9192926 — intervention group
Group type: COMPARATOR
Intervention: Hudson nebulizer and Pulmo‐Aide compressor
Number of subjects: 173
Study 1587075 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg sustained-release fenfluramine plus 15 mg phentermine resin
Number of subjects: 52
Study 1587075 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to behavior modification, caloric restriction, and exercise
Number of subjects: 52
Study 1587075 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial receipt of medication (fenfluramine plus phentermine)
Number of subjects: 52
Study 1587075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1587075 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication (fenfluramine plus phentermine)
Number of subjects: 52
Study 4028808 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline ('Trental' 400) 3 times daily for 8 weeks
Number of subjects: 90
Study 4028808 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg co-dergocrine mesylate 3 times daily for 8 weeks
Number of subjects: 90
Study 4028808 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 90
Study 29428925 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm pacemaker (DP) plus YiqiDitanTongfu (YDTF) decoction
Number of subjects: 287
Study 29428925 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm pacemaker (DP)
Number of subjects: 287
Study 30938581 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 84
Study 30938581 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients
Number of subjects: 84
Study 30938581 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study 30103444 — intervention group
Group type: EXPERIMENTAL
Intervention: High Mediterranean diet score
Number of subjects: 2568
Study 30103444 — intervention group
Group type: COMPARATOR
Intervention: Low Mediterranean diet score
Number of subjects: 2568
Study 26924405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional carbon dioxide laser combined with intradermal platelet-rich plasma treatment
Number of subjects: 16
Study 26924405 — intervention group
Group type: COMPARATOR
Intervention: Ablative fractional carbon dioxide laser with intradermal normal saline
Number of subjects: 16
Study 24565103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheathed speculum
Number of subjects: 136
Study 22853873 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational group intervention
Number of subjects: 100
Study 22853873 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 100
Study 19874728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 0
Study 19874728 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 0
Study 19874728 — intervention group
Group type: COMPARATOR
Intervention: Antihistamines, antihistamine‐decongestant combinations, guaifenesin
Number of subjects: 0
Study 19874728 — intervention group
Group type: COMPARATOR
Intervention: Antihistamines, decongestants, DM, or combinations
Number of subjects: 0
Study 19874728 — intervention group
Group type: COMPARATOR
Intervention: Zinc
Number of subjects: 0
Study 17360720 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) based on the FRAMES protocol
Number of subjects: 90
Study 17360720 — intervention group
Group type: COMPARATOR
Intervention: Simple Advice (SA)
Number of subjects: 90
Study 14612894 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (standard schedule)
Number of subjects: 50
Study 14612894 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (fixed dose rate schedule)
Number of subjects: 50
Study 14612894 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (both schedules)
Number of subjects: 50
Study 11087784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (single infusion)
Number of subjects: 0
Study 11087784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 9195523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 17
Study 9195523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 17
Study 9195523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 17
Study 1534166 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 11
Study 1534166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 11
Study 1534166 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 11
Study 3896594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovo-lacto-vegetarian (OLV) diet for 6 weeks
Number of subjects: 58
Study 3896594 — intervention group
Group type: COMPARATOR
Intervention: Usual diet maintained for 12 weeks
Number of subjects: 58
Study 31431683 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-value risk model
Number of subjects: 5105
Study 31431683 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-based model
Number of subjects: 5105
Study 31431683 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of risk model
Number of subjects: 5105
Study 30178038 — intervention group
Group type: EXPERIMENTAL
Intervention: ddMVAC
Number of subjects: 824
Study 30178038 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine-cisplatin
Number of subjects: 824
Study 30178038 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine-carboplatin
Number of subjects: 824
Study 30178038 — intervention group
Group type: COMPARATOR
Intervention: ddMVAC vs gemcitabine-cisplatin
Number of subjects: 824
Study 27275059 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 60
Study 27275059 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam
Number of subjects: 60
Study 25273343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and capecitabine (bevacizumab 15 mg/kg on day 1; capecitabine 1000 mg/m2 twice per day on days 1-14, every 3 weeks)
Number of subjects: 185
Study 25273343 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab only (15 mg/kg on day 1)
Number of subjects: 185
Study 25273343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and capecitabine
Number of subjects: 185
Study 25273343 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab only
Number of subjects: 185
Study 22497823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 421
Study 22497823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 19934097 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified catheters (MC) with SMA coating
Number of subjects: 16
Study 19934097 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheters (CC)
Number of subjects: 16
Study 17869409 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 120
Study 17869409 — intervention group
Group type: COMPARATOR
Intervention: Open prostatectomy (OP)
Number of subjects: 120
Study 15767470 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg) for 12 weeks
Number of subjects: 18
Study 15767470 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 18
Study 15767470 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg) for 12 weeks
Number of subjects: 18
Study 12925422 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation clinics
Number of subjects: 221
Study 12925422 — intervention group
Group type: COMPARATOR
Intervention: Family physicians
Number of subjects: 221
Study 11272364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy using the Galileo Centering Catheter
Number of subjects: 312
Study 9139273 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ACE activity in patients with mild and moderate hypertension
Number of subjects: 50
Study 9139273 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ACE activity in patients with left ventricular hypertrophy
Number of subjects: 50
Study 9139273 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ACE activity and left ventricular mass indexes
Number of subjects: 50
Study 9139273 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ACE activity and blood pressure levels
Number of subjects: 50
Study 1660514 — intervention group
Group type: EXPERIMENTAL
Intervention: Human alpha-ANP infusion at 0.01 micrograms/kg per min
Number of subjects: 6
Study 1660514 — intervention group
Group type: COMPARATOR
Intervention: Placebo ANP infusion
Number of subjects: 6
Study 7120015 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood state of elation
Number of subjects: 0
Study 7120015 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood state of depression
Number of subjects: 0
Study 7120015 — intervention group
Group type: COMPARATOR
Intervention: Ineffective mood inductions
Number of subjects: 0
Study 30526074 — intervention group
Group type: EXPERIMENTAL
Intervention: Group executive function training (GEFT)
Number of subjects: 81
Study 30526074 — intervention group
Group type: COMPARATOR
Intervention: Social skills training (SST)
Number of subjects: 81
Study 30782719 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal integrative intervention incorporating relaxation, guided imagery, and moderate pressure touch massage for up to five consecutive days.
Number of subjects: 104
Study 30782719 — intervention group
Group type: COMPARATOR
Intervention: Standard care and a sham intervention.
Number of subjects: 104
Study 27842383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) for 12 weeks
Number of subjects: 114
Study 27842383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) for 24 weeks
Number of subjects: 114
Study 27842383 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events overall
Number of subjects: 114
Study 25145934 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐21 expression in glomerular fractions
Number of subjects: 48
Study 25145934 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐21 deficiency in TGF‐β(1)‐transgenic mice
Number of subjects: 48
Study 25145934 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of miR‐21 in cultured podocytes
Number of subjects: 48
Study 23963786 — intervention group
Group type: EXPERIMENTAL
Intervention: PA + WL (n=98)
Number of subjects: 288
Study 23963786 — intervention group
Group type: COMPARATOR
Intervention: PA-only (n=97)
Number of subjects: 288
Study 23963786 — intervention group
Group type: COMPARATOR
Intervention: SA control (n=93)
Number of subjects: 288
Study 21937805 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive limb ischemic preconditioning (NIPC)
Number of subjects: 32
Study 21937805 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 19539316 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sutures
Number of subjects: 80
Study 19539316 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 80
Study 17709451 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg) and vitamin B-12 (1.25 mg) supplementation
Number of subjects: 86
Study 17709451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 12612213 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental glycerol at 5 micromol/kg x min
Number of subjects: 20
Study 12612213 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental glycerol at 10 micromol/kg x min
Number of subjects: 20
Study 12612213 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone (control group)
Number of subjects: 20
Study 10562586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide enhanced ultrasound (US)-fistulography
Number of subjects: 17
Study 10562586 — intervention group
Group type: COMPARATOR
Intervention: Conventional x ray fistulogram
Number of subjects: 17
Study 10562586 — intervention group
Group type: COMPARATOR
Intervention: Barium radiography
Number of subjects: 17
Study 8733881 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH screening program using a supersensitive TSH assay
Number of subjects: 1880
Study 8733881 — intervention group
Group type: EXPERIMENTAL
Intervention: Full thyroid function testing
Number of subjects: 1880
Study 8733881 — intervention group
Group type: EXPERIMENTAL
Intervention: Full assessment of 600 subjects
Number of subjects: 1880
Study 8733881 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of antithyroid antibodies
Number of subjects: 1880
Study 8733881 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related changes in free T4 and free T3
Number of subjects: 1880
Study 8733881 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related changes in free T3/free T4 ratio
Number of subjects: 1880
Study 1860625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 24
Study 1860625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 24
Study 1860625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1860625 — intervention group
Group type: EXPERIMENTAL
Intervention: Food ingestion
Number of subjects: 24
Study 1860625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham feeding
Number of subjects: 24
Study 7159691 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorbutol (oral administration)
Number of subjects: 4
Study 7159691 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorbutol (second dose)
Number of subjects: 4
Study 7159691 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorbutol (urinary recovery)
Number of subjects: 4
Study 7159691 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorbutol (in vitro stability)
Number of subjects: 4
Study 7159691 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorbutol (multiple doses)
Number of subjects: 4
Study 30955351 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading vignettes describing fictitious older adults with memory impairment
Number of subjects: 200
Study 30955351 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading vignettes that included descriptions of BPSD
Number of subjects: 200
Study 30955351 — intervention group
Group type: COMPARATOR
Intervention: Control group (responded to questionnaire without reading any vignette)
Number of subjects: 200
Study 31104167 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma 25-hydroxyvitamin D3 (25(OH)D) levels
Number of subjects: 535
Study 31104167 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score based on 25(OH)D-associated SNPs
Number of subjects: 535
Study 31104167 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D levels and rs12785878 genotype in DHCR7
Number of subjects: 535
Study 29023839 — intervention group
Group type: EXPERIMENTAL
Intervention: Salud-100 intervention (all families received the intervention)
Number of subjects: 27
Study 29023839 — intervention group
Group type: EXPERIMENTAL
Intervention: Salud-50 intervention (families either received booklets or the intervention)
Number of subjects: 27
Study 29023839 — intervention group
Group type: COMPARATOR
Intervention: Control group (families received booklets on healthy eating and exercise)
Number of subjects: 27
Study 25921544 — intervention group
Group type: EXPERIMENTAL
Intervention: 33 °C treatment group
Number of subjects: 939
Study 25921544 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 °C treatment group
Number of subjects: 939
Study 22990757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dang Gui Buxue Tang (DBT) 3.0 g/day
Number of subjects: 60
Study 22990757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dang Gui Buxue Tang (DBT) 6.0 g/day
Number of subjects: 60
Study 22990757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dang Gui Buxue Tang (DBT) 1.5 g/day
Number of subjects: 60
Study 21724703 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygosity of the rs1800802 minor allele
Number of subjects: 376
Study 21724703 — intervention group
Group type: COMPARATOR
Intervention: Serum MGP concentrations
Number of subjects: 376
Study 20376999 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (2 mg/kg), epinephrine (100 microg), and fentanyl (2.5 microg/kg)
Number of subjects: 40
Study 20376999 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (2 mg/kg) and epinephrine (100 microg)
Number of subjects: 40
Study 16571906 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal stance condition
Number of subjects: 0
Study 16571906 — intervention group
Group type: EXPERIMENTAL
Intervention: Resist influence condition
Number of subjects: 0
Study 16571906 — intervention group
Group type: COMPARATOR
Intervention: Eyes closed condition
Number of subjects: 0
Study 14988279 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17‐beta‐estradiol
Number of subjects: 673
Study 10360656 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) combined with human interferon-beta (IFN-beta)
Number of subjects: 49
Study 10360656 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 49
Study 8951752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel‐coated balloon catheters delivered with heparin coating (n = 33)
Number of subjects: 59
Study 8951752 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel‐coated balloon catheters without heparin coating (n = 26)
Number of subjects: 59
Study 2019820 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustments
Number of subjects: 171
Study 6177709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IGIV) at a dose of 20 ml/kg, administered twenty-four hours post transplantation and then weekly for 10 weeks.
Number of subjects: 13
Study 6177709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IGIV)
Number of subjects: 13
Study 30606135 — intervention group
Group type: EXPERIMENTAL
Intervention: C-DIRECT intervention (nurse-led intervention based on motivational interviewing and self-management)
Number of subjects: 44
Study 30606135 — intervention group
Group type: EXPERIMENTAL
Intervention: C-DIRECT intervention
Number of subjects: 44
Study 30606135 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study 30606135 — intervention group
Group type: EXPERIMENTAL
Intervention: C-DIRECT intervention and Usual care
Number of subjects: 44
Study 30304745 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG self-monitoring using mHealth technology for 6 months
Number of subjects: 13
Study 26956161 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture, three times a week for 4 weeks
Number of subjects: 88
Study 26956161 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (superficial insertion at irrelevant acupuncture points), three times a week for 4 weeks
Number of subjects: 88
Study 25085836 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride and placebo treatment arms
Number of subjects: 3377
Study 25085836 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 3377
Study 25085836 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment arms
Number of subjects: 3377
Study 25085836 — intervention group
Group type: EXPERIMENTAL
Intervention: Men ≥65 years
Number of subjects: 3377
Study 25085836 — intervention group
Group type: EXPERIMENTAL
Intervention: Men 55-64 years
Number of subjects: 3377
Study 23091707 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacements (MRs) - 2 MR/day for 3 months and 1 MR/day for 3 months
Number of subjects: 120
Study 23091707 — intervention group
Group type: COMPARATOR
Intervention: Diet book (control)
Number of subjects: 120
Study 23091707 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacements (MRs) - intention-to-treat analysis
Number of subjects: 120
Study 23091707 — intervention group
Group type: COMPARATOR
Intervention: Diet book (control) - intention-to-treat analysis
Number of subjects: 120
Study 23091707 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacements (MRs)
Number of subjects: 120
Study 23091707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 20570122 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein aglycone (54 mg/day)
Number of subjects: 56
Study 20570122 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (10 mg/day on days 16-25 of the menstrual cycle)
Number of subjects: 56
Study 20570122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18043573 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐octyl‐cyanoacrylate (2‐OCA) glue
Number of subjects: 310
Study 18043573 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐reabsorbable intradermal suture
Number of subjects: 310